Rhythm Pharmaceuticals annuncia l’autorizzazione da parte della Commissione europea di IMCIVREE® (setmelanotide)▼ per il trattamento dell’obesità e il controllo della fame associati a deficit di POMC, PCSK1 e LEPR

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Bud Bilanich
Success Coach

Daniel Sontupe
Market Access

Joey Cohen
Medication Adherence

David Linetsky
Point-of-Care Marketing

Liz Kane
Impactful Strategy

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling